Skip to main content

$0.005 (0%)

High

$0.01

Low

$0.01

Trades

3

Turnover

$2,010

Volume

402,075
30 June 2023 at 11:45am
Register to track AVE and receive email alerts.
Subject
AVE Ann: Update - Application for quotation of securities - AVE

AVE Ann: Application for quotation of securities - AVE

AVE Ann: AVE CBD capsule passes two-year stability milestone

AVE Ann: AVE adds TPM cannabinoid gummies to portfolio

AVE Ann: USPTO allows new TPM manufacturing patent

AVE Ann: 2023 Annual General Meeting Results

AVE Ann: Chair's Address and CEO Presentation

AVE Ann: Avecho licenses TPM for use in cancer drugs

AVE Ann: Withdrawal of AGM Resolutions 5(c) and 5(d)

AVE Ann: AVE commences manufacturing for Phase III trial

AVE Ann: Change in Substantial Holding

AVE Ann: Change of Director's Interest Notice x2

AVE Ann: Top 20 Option Holders

AVE Ann: Application for quotation of securities - AVE

AVE Ann: Results of Entitlement Offer

AVE Ann: Receipt of R&D Tax Incentive

AVE Ann: March 2023 Quarterly Activities Report & Appendix 4C

AVE Ann: Notice of Annual General Meeting/Proxy Form

AVE Ann: Notice to Ineligible Foreign Shareholders

AVE Ann: Notice to Eligible Shareholders

AVE Ann: Letter to Optionholders

AVE Ann: Target Market Determination

AVE Ann: Proposed issue of securities - AVE

AVE Ann: Investor Presentation

AVE Ann: Prospectus

AVE Ann: Entitlement Offer to raise $11m for Phase 3 clinical trial

AVE Ann: Avecho to present at NWR Virtual Healthcare Conference

AVE Ann: Appendix 4G and Corporate Governance Statement

AVE Ann: Annual Report - 31 December 2022

AVE Ann: Appendix 4E - Preliminary Final Report

AVE Ann: Clinical CBD program expands with the Lambert Initiative

AVE Ann: December 2022 Quarterly Activities Report & Appendix 4C

AVE Ann: Athenex submits Avecho's phytonadione to FDA pre-IND

AVE Ann: Avecho receives ethics approval for Phase III CBD trial

AVE Ann: AVE signs development agreement with Perrigo

AVE Ann: September 2022 Quarterly Activities Report & Appendix 4C

AVE Ann: Increased CBD absorption in dogs vs commercial comparator

AVE Ann: Application for quotation of securities - AVE

AVE Ann: Section 708A Cleansing Statement

AVE Ann: Appendix 4D and Half-year Financial Report

AVE Ann: June 2022 Quarterly Activities Report & Appendix 4C

AVE Ann: Security Class Reinstatement to Quotation- AVEO

AVE Ann: Update on Listed Options and Federal Court Application

AVE Ann: Suspension from Official Quotation - AVEO

AVE Ann: Adoption of New Constitution

AVE Ann: 2022 Annual General Meeting Results

AVE Ann: Chair's Address and CEO Presentation

AVE Ann: Receipt of R&D Tax Incentive

AVE Ann: March 2022 Quarterly Activities Report & Appendix 4C

AVE Ann: Notice of Annual General Meeting/Proxy Form

Register to track AVE and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL